Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10596-10606

  Abedalthagafi, Malak S ^a   Merrill, Parker H ^a   Bi, Wenya Linda ^a   Jones, Robert T ^a   Listewnik, Marc L ^a   Ramkissoon, Shakti H ^a   Thorner, Aaron R ^b   Dunn, Ian F ^a   Beroukhim, Rameen ^b,c   Alexander, Brian M ^a   Brastianos, Priscilla K ^b,c,d   Francis, Joshua M ^b,c   Folkerth, Rebecca D ^a   Ligon, Keith L ^a,b   Van Hummelen, Paul ^b   Ligon, Azra H ^a   Santagata, Sandro ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

aCGH; Angiomatous; Meningioma; Molecular diagnostics; Next generation sequencing; Polysomy

Indexed keywords

DNA; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; AMPLICON; ANGIOMATOUS MENINGIOMA; ARTICLE; CANCER GRADING; CANCER TISSUE; CARCINOGENESIS; CHROMOSOME 13; CHROMOSOME 20; CHROMOSOME 22; CHROMOSOME 5; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA ISOLATION; EXON; FEMALE; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; MONOSOMY; NUMERICAL CHROMOSOME ABERRATION; POLYSOMY; TUMOR GENE; VERY ELDERLY; YOUNG ADULT; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY;

BIOMARKERS, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; EXONS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MUTATION; NEOPLASM GRADING; TRANSCRIPTOME;

EID: 84916920305     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2517     Document Type: Article

References (44)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
2. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD and von Deimling A. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol. 1995; 146(4):827-832.
3. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K and et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993; 72(5):791-800.
4. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP and et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994; 6(2):180-184.
5. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT and Yang I. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus. 2011; 30(5):E6.
6. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013; 45(3):285-289.
7. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013; 339(6123):1077-1080.
8. Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol. 2013; 125(3):351-358.
9. Hasselblatt M, Nolte KW and Paulus W. Angiomatous meningioma: a clinicopathologic study of 38 cases. Am J Surg Pathol. 2004; 28(3):390-393.
10. Liu Z, Wang C, Wang H, Wang Y, Li JY and Liu Y. Clinical characteristics and treatment of angiomatous meningiomas: a report of 27 cases. Int J Clin Exp Pathol. 2013; 6(4):695-702.
11. Janowska K, Kordek R, Biernat W, Liberski PP, Krul W and Debiec-Rychter M. Biologic heterogeneity of angiomatous meningiomas. Pol J Pathol. 1998; 49(4):279-284.
12. Hartmann C, Sieberns J, Gehlhaar C, Simon M, Paulus W and von Deimling A. NF2 mutations in secretory and other rare variants of meningiomas. Brain pathology. 2006; 16(1):15-19.
13. Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881.
14. Glasker S, Bender BU, Apel TW, van Velthoven V, Mulligan LM, Zentner J and Neumann HP. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 2001; 70(5):644-648.
15. Gijtenbeek JM, Jacobs B, Sprenger SH, Eleveld MJ, van Kessel AG, Kros JM, Sciot R, van Calenbergh F, Wesseling P and Jeuken JW. Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg. 2002; 97(4):977-982.
16. Perry A, Scheithauer BW, Stafford SL, Lohse CM and Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999; 85(9):2046-2056.
17. Gray SW, Hicks-Courant K, Cronin A, Rollins BJ and Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014; 32(13):1317-1323.
18. Pfau SJ and Amon A. Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep. 2012; 13(6):515-527.
19. Donnelly N, Passerini V, Durrbaum M, Stingele S and Storchova Z. HSF1 deficiency and impaired HSP90-dependent protein folding are hallmarks of aneuploid human cells. The EMBO journal. 2014.
20. Siegel JJ and Amon A. New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol. 2012; 28:189-214.
21. Tang YC and Amon A. Gene copy-number alterations: a cost-benefit analysis. Cell. 2013; 152(3):394-405.
22. Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, Bronson RT, Whitesell L and Lindquist S. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. The Journal of clinical investigation. 2012; 122(10):3742-3754.
23. Santagata S, Xu YM, Wijeratne EM, Kontnik R, Rooney C, Perley CC, Kwon H, Clardy J, Kesari S, Whitesell L, Lindquist S and Gunatilaka AA. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol. 2012; 7(2):340-349.
24. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL and Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011; 475(7355):231-234.
25. Adams DJ, Dai M, Pellegrino G, Wagner BK, Stern AM, Shamji AF and Schreiber SL. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A. 2012; 109(38):15115-15120.
26. Tang YC, Williams BR, Siegel JJ and Amon A. Identification of aneuploidy-selective antiproliferation compounds. Cell. 2011; 144(4):499-512.
27. Santagata S, Mendillo ML, Tang YC, Subramanian A, Perley CC, Roche SP, Wong B, Narayan R, Kwon H, Koeva M, Amon A, Golub TR, Porco JA, Jr., Whitesell L and Lindquist S. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science. 2013; 341(6143):1238303.
28. Solimini NL, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, Burrows AE, Anselmo AN, Bredemeyer AL, Li MZ, Beroukhim R, Meyerson M and Elledge SJ. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science. 2012; 337(6090):104-109.
29. Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ and Elledge SJ. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013; 155(4):948-962.
30. Nassehi D, Sorensen LP, Dyrbye H, Thomsen C, Juhler M, Laursen H and Broholm H. Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway. APMIS. 2013; 121(11):1025-1036.
31. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ and Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain pathology. 2014; 24(2):184-189.
32. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, Wittmann A, Yao Y, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011; 20(2):143-157.
33. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jager N, Jones DT, Sill M, Pugh TJ, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014; 506(7489):445-450.
34. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schottler A, Kulozik AE, Witt O, von Deimling A, Lichter P and Pfister S. Molecular staging of intracranial ependymoma in children and adults. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(19):3182-3190.
35. Ketter R, Kim YJ, Storck S, Rahnenfuhrer J, Romeike BF, Steudel WI, Zang KD and Henn W. Hyperdiploidy defines a distinct cytogenetic entity of meningiomas. Journal of neuro-oncology. 2007; 83(2):213-221.
36. Venkatraman ES and Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007; 23(6):657-663.
37. Olshen AB, Venkatraman ES, Lucito R and Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004; 5(4):557-572.
38. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R and Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41.
39. Nilsen G, Liestol K, Van Loo P, Moen Vollan HK, Eide MB, Rueda OM, Chin SF, Russell R, Baumbusch LO, Caldas C, Borresen-Dale AL and Lingjaerde OC. Copynumber: Efficient algorithms for single- and multitrack copy number segmentation. BMC Genomics. 2012; 13:591.
40. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80.
41. Li H and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-1760.
42. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-1303.
43. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43(5):491-498.
44. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES and Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-219.